What beta blockers, calcium channel blockers, and other treatments are used in atrial fibrillation, including their side effects and drug interactions?

Rate Control in Atrial Fibrillation: Beta-Blockers and Calcium Channel Blockers

Beta-blockers (specifically metoprolol) are the first-line agents for rate control in atrial fibrillation, achieving target heart rate in 70% of patients compared to 54% with calcium channel blockers, with nondihydropyridine calcium channel blockers (diltiazem, verapamil) reserved for patients with contraindications to beta-blockers or as combination therapy. 1, 2

Beta-Blockers for Rate Control

Preferred Agents and Dosing

Metoprolol is the preferred initial beta-blocker for AF rate control based on the most robust evidence from the AFFIRM trial 1, 2:

• Acute IV dosing: Metoprolol tartrate 2.5-5 mg bolus over 2 minutes, up to 3 doses 1, 2
• Oral maintenance: Metoprolol tartrate 25-200 mg twice daily OR metoprolol succinate 50-400 mg daily 1
• Half-life: 3-4 hours (tartrate), 3-7 hours (succinate) 1

Alternative Beta-Blockers

Other beta-blockers with established efficacy include 1:

• Atenolol: 25-100 mg daily (renally eliminated—requires dose adjustment in renal impairment) 1
• Bisoprolol: 2.5-10 mg daily 1
• Carvedilol: 3.125-25 mg twice daily (has additional alpha-blocking properties) 1, 3
• Esmolol: 500 μg/kg bolus, then 50-300 μg/kg/min infusion (ultra-short acting, 9-minute half-life—useful for critically ill patients) 1

Beta-Blocker Advantages

Beta-blockers provide superior rate control during both rest and exercise compared to digoxin, making them ideal for active patients 1, 4. They are particularly effective when combined with digoxin if monotherapy fails 1.

---

Nondihydropyridine Calcium Channel Blockers

When to Use CCBs

Diltiazem and verapamil are appropriate alternatives when beta-blockers are contraindicated (e.g., bronchospasm, severe COPD) or as combination therapy 1:

• Diltiazem: More effective than verapamil for rate reduction in head-to-head comparisons 5
• Both agents improve quality of life and exercise tolerance 1

Dosing Regimens

Diltiazem 1:

• IV: 0.25 mg/kg over 2 minutes; may repeat 0.35 mg/kg, then 5-15 mg/h infusion
• Oral: 120-360 mg daily (extended release)
• Half-life: IV 3-5 hours, oral immediate release 3-4.5 hours, ER 4-9.5 hours

Verapamil 1:

• IV: 5-10 mg over ≥2 minutes (may repeat twice), then 5 mg/h infusion (max 20 mg/h)
• Oral: 180-480 mg daily (extended release)
• Half-life: IV 6-8 hours, oral 2-7 hours, ER 12-17 hours

Critical CCB Contraindication

Avoid diltiazem and verapamil in heart failure with reduced ejection fraction (HFrEF) due to negative inotropic effects that worsen hemodynamic compromise (Class III recommendation) 1, 2. A 2022 study demonstrated significantly higher rates of worsening heart failure symptoms with diltiazem versus metoprolol in HFrEF patients (33% vs 15%, p=0.019) 6.

---

Digoxin: Limited Role

Digoxin should NOT be used as sole therapy for rate control (Class III recommendation) 1:

• Delayed onset: 60 minutes to effect, peak at 6 hours 1
• Ineffective during exercise or high sympathetic tone 1, 7
• No better than placebo for conversion to sinus rhythm 1

When Digoxin Is Appropriate

Digoxin is acceptable for 1:

• Patients with HFrEF or LV dysfunction (positive inotropic effect)
• Sedentary patients (rate control at rest only needed)
• Combination therapy with beta-blockers or CCBs when monotherapy fails (Class IIa recommendation) 1, 7

Dosing: 0.25-0.5 mg IV loading, then 0.0625-0.25 mg daily oral maintenance 1

Critical warning: Mortality increases at plasma concentrations >1.2 ng/mL; renally eliminated requiring dose adjustment 1

---

Amiodarone for Refractory Cases

Intravenous amiodarone is reserved for rate control when other measures fail or are contraindicated (Class IIa/IIb recommendation) 1, 7:

• IV loading: 150-300 mg over 1 hour, then 10-50 mg/h over 24 hours 1
• Oral maintenance: 100-200 mg daily (after 6-10 g loading over 2-4 weeks) 1
• Extremely long half-life: IV 9-36 days, oral 26-107 days 1

Amiodarone is particularly useful in critically ill patients refractory to conventional agents 1, 7.

---

Side Effects and Monitoring

Beta-Blocker Side Effects 1, 3

• Bradycardia and heart block (especially with digoxin or CCBs)
• Hypotension (particularly with carvedilol due to alpha-blockade)
• Bronchospasm (avoid in severe asthma/COPD)
• Masking of hypoglycemic symptoms in diabetics (not an absolute contraindication) 2, 3
• Fatigue and exercise intolerance
• Worsening claudication (uncommon—metoprolol generally safe in peripheral arterial disease) 2

Calcium Channel Blocker Side Effects 1, 3

• Hypotension (additive with beta-blockers)
• Bradycardia and AV block (especially with beta-blockers or digoxin)
• Negative inotropy (contraindicated in HFrEF)
• Peripheral edema
• Constipation (verapamil more than diltiazem)
• Conduction disturbances when combined with carvedilol (rarely with hemodynamic compromise) 3

Digoxin Side Effects 1

• Bradycardia and AV block
• Proarrhythmia (increased with concurrent digoxin and sotalol) 8
• GI symptoms (nausea, vomiting)
• Visual disturbances
• Increased mortality at levels >1.2 ng/mL 1

Amiodarone Side Effects 1

• Pulmonary toxicity (potentially fatal)
• Thyroid dysfunction (hypo- or hyperthyroidism)
• Hepatotoxicity (monitor AST/ALT within first 6 months) 1
• Corneal deposits and optic neuropathy 1
• Skin discoloration and photosensitivity
• Bradycardia and QT prolongation

---

Drug Interactions

Beta-Blocker Interactions 8, 3

• Digoxin: Additive AV nodal blockade; digoxin levels increase ~15% with carvedilol—monitor closely 3
• Calcium channel blockers: Additive bradycardia and hypotension; ECG monitoring recommended with diltiazem/verapamil 3
• Catecholamine-depleting agents (reserpine, guanethidine): Excessive sympathetic tone reduction, severe hypotension/bradycardia 8, 3
• Clonidine: Potentiated rebound hypertension if clonidine discontinued—taper beta-blocker first 8, 3
• Insulin/oral hypoglycemics: Enhanced glucose-lowering effect; may mask hypoglycemia symptoms 3
• Amiodarone: Inhibits CYP2C9, increasing carvedilol levels 2-fold—observe for excessive bradycardia 3
• CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine): Increase R(+) enantiomer of carvedilol, causing more dizziness 3
• Cyclosporine: Carvedilol increases cyclosporine levels ~20%—monitor levels closely 3

Calcium Channel Blocker Interactions 1, 3

• Beta-blockers: Additive negative chronotropy and inotropy; conduction disturbances possible 3
• Digoxin: Additive AV nodal suppression; increased bradycardia risk 1
• Antihypertensives: Additive hypotensive effects 8

Digoxin Interactions 8, 3

• Beta-blockers and CCBs: Additive AV nodal blockade 1, 3
• Amiodarone: Increases digoxin levels—dose reduction often needed 1
• Sotalol: Increased proarrhythmic events (unclear if interaction or CHF-related) 8

Amiodarone Interactions 1, 3

• Warfarin: Significant interaction requiring INR monitoring and dose adjustment 1
• Digoxin: Increases digoxin levels 1
• Beta-blockers: Inhibits CYP2C9, doubling carvedilol S(-) enantiomer levels—monitor for excessive bradycardia 3
• QT-prolonging drugs: Additive risk of torsades de pointes 1

Sotalol Interactions 8

• Digoxin: More proarrhythmic events (mechanism unclear) 8
• Calcium channel blockers: Additive effects on AV conduction and ventricular function 8
• Antacids: Reduce sotalol absorption by 25%—administer 2 hours apart 8
• Catecholamine-depleting agents: Excessive hypotension/bradycardia 8

---

Practical Algorithm for Agent Selection

Step 1: Assess Hemodynamic Stability

• Unstable: Proceed to electrical cardioversion 2
• Stable: Continue to Step 2

Step 2: Evaluate for Heart Failure

• HFrEF present: Use metoprolol (avoid diltiazem/verapamil) 1, 2, 6
• No HFrEF: Continue to Step 3

Step 3: Assess for Pulmonary Disease

• Severe asthma/COPD: Use diltiazem or verapamil (avoid beta-blockers) 1, 2
• No contraindication: Use metoprolol as first-line 1, 2

Step 4: Consider Comorbidities

• Diabetes: Metoprolol or diltiazem acceptable (beta-blockers may mask hypoglycemia but not contraindicated) 2, 3
• Peripheral arterial disease: Metoprolol preferred (does not significantly worsen claudication) 2
• Sedentary patient with HFrEF: Digoxin acceptable but not as monotherapy 1, 7

Step 5: If Monotherapy Fails

• Add digoxin to beta-blocker or CCB (Class IIa recommendation) 1, 7
• Consider amiodarone if refractory to combination therapy 1, 7

Step 6: Monitoring

• Beta-blockers: Reassess heart rate after 5-10 minutes IV; monitor for bradycardia, hypotension 2, 7
• CCBs: Monitor blood pressure and ECG for conduction abnormalities 3
• Digoxin: Check renal function, electrolytes (K+, Mg2+), and levels (target <1.2 ng/mL) 1
• Amiodarone: Baseline and follow-up ECG, liver function tests, thyroid function, pulmonary function 1

---

Common Pitfalls to Avoid

• Using digoxin as monotherapy for rate control—ineffective during exercise and high sympathetic states 1, 7
• Administering CCBs in HFrEF—significantly worsens heart failure symptoms 1, 2, 6
• Combining beta-blockers and CCBs without ECG monitoring—risk of severe bradycardia and heart block 3
• Discontinuing clonidine before beta-blockers—causes rebound hypertension; taper beta-blocker first 8, 3
• Ignoring renal function with atenolol or digoxin—both renally eliminated and require dose adjustment 1
• Administering sotalol with antacids—reduces absorption by 25%; separate by 2 hours 8
• Failing to monitor cyclosporine levels with carvedilol—levels increase ~20%, requiring dose reduction in 30% of patients 3